Kaempferol, quercetin, and stigmasterol are the main active compounds in the JPYF II Formula in the treatment of COPD, and AKT1, IL-6, and TNF are potential target proteins for the JPYF II Formula in the treatment of COPD. This evidence concerns the gene AKT1 and chronic obstructive pulmonary disease.